AngioDynamics Net Common Equity Issued/Repurchased 2010-2025 | ANGO
AngioDynamics net common equity issued/repurchased from 2010 to 2025. Net common equity issued/repurchased can be defined as the net dollar amount of transactions to issue and repurchase common stock.
| AngioDynamics Annual Net Common Equity Issued/Repurchased (Millions of US $) |
|
|---|---|
| 2024 | $1 |
| 2023 | $1 |
| 2022 | $3 |
| 2021 | $N/A |
| 2020 | $-1 |
| 2019 | $2 |
| 2018 | $3 |
| 2017 | $-3 |
| 2016 | $2 |
| 2015 | $6 |
| 2014 | $2 |
| 2013 | $1 |
| 2012 | $1 |
| 2011 | $2 |
| 2010 | $3 |
| 2009 | $2 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MED INSTRUMENTS | $0.377B | $0.304B |
| AngioDynamics Inc. designs, manufactures and sells a wide range of medical, surgical and diagnostic devices. The devices are generally used in minimally invasive, image-guided procedures. AngioDynamics product offerings fall within three Global Business Units, namely Oncology/Surgery, Endovascular Therapies and Vascular Access. Endovascular Therapies product offerings support the medical areas of Thrombus Management, Atherectomy, Peripheral Products and Venous Insufficiency. The Thrombus Management portfolio includes the proprietary AngioVac venous drainage cannula and circuit as well as catheter directed thrombolytic devices. Vascular Access arm offers advanced imaging equipment to guide the placement of catheters that primarily deliver short-term drug therapies. IGVA procedures include the placement of Peripherally Inserted Central Catheters lines, implantable ports and central venous catheters. Oncology/Surgery division includes Microwave Ablation, Radiofrequency Ablation and NanoKnife product lines. | |||